Kiromic BioPharma, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial to evaluate KB-GDT-01, or Deltacel, in combination with an anti-tumor therapy for the treatment of non-small cell lung cancer (NSCLC). Deltacel is the Company's allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cell (GDT) therapy The Company is seeking to address the significant unmet need of applying cell therapy to treat solid malignancies, which comprise 90% of all cancers, including NSCLC.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.08 USD | +11.59% | +27.80% | +254.02% |
May. 10 | Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 01 | Kiromic BioPharma, Inc. announced that it has received $2 million in funding | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+254.02% | 3.56M | |
+7.70% | 113B | |
+10.41% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.31% | 17.24B | |
+6.72% | 14.29B | |
+36.38% | 12.52B |
- Stock Market
- Equities
- KRBP Stock
- News Kiromic BioPharma, Inc.
- Kiromic Biopharma, Inc. Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer